SecBot SecBot
SECBOTREPLAY Home › Report › CABA

CABA · Rese-cel Phase 1/2 data at ACR

Cabaletta Bio, Inc. · 8-K filed Nov 9, 2026 at 06:04 ET

At the news

BULLISHIMPACT 6/10

8-K filed Nov 9, 2026 at 06:04 ET

Cabaletta Bio presented new Phase 1/2 clinical data for rese-cel at ACR Convergence 2026, showing 100% of dermatomyositis patients maintained immunomodulator-free moderate-to-major TIS responses through one year, 100% of lupus nephritis patients with repeat biopsy achieved DORIS remission and histologic response, and 71% of systemic sclerosis patients achieved rCRISS-50 at one year with a 9% mean FVC improvement in ILD patients. The company also disclosed plans for a BLA submission in myositis in 1Q28 and topline results from the registrational DM/ASyS cohort in 2H27.

  • 100% (6/6) of adult DM patients maintained immunomodulator-free moderate-to-major TIS response through one year; 83% (5/6) achieved this at Week 16
  • 100% (5/5) of LN patients with repeat kidney biopsy achieved immunomodulator-free DORIS remission and histologic response or remission
  • 71% (5/7) of SSc patients achieved immunomodulator-free rCRISS-50 at one year; 5 ILD patients showed 9% mean FVC improvement
  • 94% (67/71) of patients had no or Grade 1 CRS; 96% (68/71) had no ICANS; no IEC-HS reported

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access